Related Experiment Video

Updated: Apr 17, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.5K

Genetic basis for clinical response to CTLA-4 blockade

Ignacio Melero, Juan J Lasarte

    The New England Journal of Medicine
    |February 19, 2015
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.3K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K

    Related Experiment Videos

    Last Updated: Apr 17, 2026

    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
    09:08

    Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

    Published on: October 14, 2021

    6.5K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.3K
    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.2K

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    72
    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    72
    T Cell Activation and Clonal Selection01:22

    T Cell Activation and Clonal Selection

    17.9K
    T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
    Naive T cells that have not yet encountered an antigen express two primary CD...
    17.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

    Cancer research·2026

    Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

    Blood·2026

    Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

    Journal for immunotherapy of cancer·2026

    Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

    Journal of hematology & oncology·2026

    Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

    Trends in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us